OF SHARED RESOURCE The Sidney Kimmel Comprehensive Cancer Center (SKCCC) Biostatistics Shared Resource (BiostatSR) consists of six doctoral-level faculty biostatisticians positions, one of which is in the process of being filled, four master's level statisticians, and two information technology specialists. BiostatSR members collaborate and consult with other Cancer Center investigators in the design, conduct, and analysis of cancer-related clinical, preclinical, laboratory, and epidemiologic investigations. BiostatSR also reviews proposals for cancer-related clinical investigations in the Protocol Review and Monitoring System-Clinical Research Review Committee (PRMS-CRC). The Biostatistics Core provides consultation and expertise regarding study design (including validity of the overall design, feasibility of meeting objectives, sample size and projection of study duration), recommendations for and development of key infrastructure (data management and computer systems support), data analysis, preparation of reports and assistance with manuscript writing, and development of new biostatistical methods if required by the project. The goal of the Biostatistics Core is to ensure that study designs, data monitoring, and analyses use state-of-the-art methods, and to help developmental studies supported by the Center garner peer-reviewed funding. This Core has experienced turnover in faculty during the grant cycle, most of whom have successfully been replaced, with a plan to undergo controlled growth during the next grant cycle amongst both faculty and staff. In addition to being strongly integrated into all Programs in the Center, biostatisticians in the Core have important intellectual ties to other professionals in the medical institutions who are engaged in similar activities in other disciplines. This diverse environment provides SKCCC investigators with strong, broad-based biostatistical expertise that is always accessible Plans for the future of Biostatistics include collaboration in initiatives in information systems to support clinical and basic science research data, and development of a centerwide Program in quantitative cancer research. Lay: This Core provides consultation and expertise regarding study design, recommendations for and development of key infrastructure, data analysis, preparation of reports and assistance with manuscript writing, and development of new biostatistical methods if required by the project. Cancer Center Managed Shared Resource Current Grant Year Reporting Period: January 1, 2010 to December 31, 2010 .

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-50
Application #
8559717
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
50
Fiscal Year
2013
Total Cost
$531,276
Indirect Cost
$203,328
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Gorin, Michael A; Rowe, Steven P; Patel, Hiten D et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 199:126-132
Jiang, Wei; Zhou, Xiaoyan; Li, Zengxia et al. (2018) Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin. Blood 131:1325-1336
Nagai, Kozo; Hou, Lihong; Li, Li et al. (2018) Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885-32899
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:

Showing the most recent 10 out of 2393 publications